Advertisement
Australia markets closed
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • AUD/USD

    0.6604
    -0.0017 (-0.26%)
     
  • OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD

    2,366.90
    +26.60 (+1.14%)
     
  • Bitcoin AUD

    91,991.74
    -3,773.95 (-3.94%)
     
  • CMC Crypto 200

    1,256.28
    -101.73 (-7.49%)
     
  • AUD/EUR

    0.6128
    -0.0010 (-0.16%)
     
  • AUD/NZD

    1.0963
    -0.0006 (-0.05%)
     
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NASDAQ

    18,161.18
    +47.72 (+0.26%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • Dow Jones

    39,512.84
    +125.08 (+0.32%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

Top Ranked Growth Stocks to Buy for January 22nd

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, January 22nd:

Legg Mason, Inc. (LM): This asset management holding company, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.7% over the last 60 days.

Legg Mason, Inc. Price and Consensus

Legg Mason, Inc. Price and Consensus
Legg Mason, Inc. Price and Consensus

Legg Mason, Inc. price-consensus-chart | Legg Mason, Inc. Quote

Legg Mason has a PEG ratio of 0.77, compared with 1.24 for the industry. The company possesses a Growth Score of B.

Legg Mason, Inc. PEG Ratio (TTM)

Legg Mason, Inc. PEG Ratio (TTM)
Legg Mason, Inc. PEG Ratio (TTM)

Legg Mason, Inc. peg-ratio-ttm | Legg Mason, Inc. Quote

ADVERTISEMENT

Alexion Pharmaceuticals, Inc. (ALXN): This company that develops and commercializes various therapeutic products, carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.7% over the last 60 days.

Alexion Pharmaceuticals, Inc. Price and Consensus

Alexion Pharmaceuticals, Inc. Price and Consensus
Alexion Pharmaceuticals, Inc. Price and Consensus

Alexion Pharmaceuticals, Inc. price-consensus-chart | Alexion Pharmaceuticals, Inc. Quote

Alexion has a PEG ratio of 0.72, compared with 0.85 for the industry. The company possesses a Growth Score of B.

Alexion Pharmaceuticals, Inc. PEG Ratio (TTM)

Alexion Pharmaceuticals, Inc. PEG Ratio (TTM)
Alexion Pharmaceuticals, Inc. PEG Ratio (TTM)

Alexion Pharmaceuticals, Inc. peg-ratio-ttm | Alexion Pharmaceuticals, Inc. Quote

TopBuild Corp. (BLD): This installer and distributor of insulation and building material products, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.7% over the last 60 days.

TopBuild Corp. Price and Consensus

TopBuild Corp. Price and Consensus
TopBuild Corp. Price and Consensus

TopBuild Corp. price-consensus-chart | TopBuild Corp. Quote

TopBuild has a PEG ratio of 0.65, compared with 1.41 for the industry. The company possesses a Growth Score of A.

TopBuild Corp. PEG Ratio (TTM)

TopBuild Corp. PEG Ratio (TTM)
TopBuild Corp. PEG Ratio (TTM)

TopBuild Corp. peg-ratio-ttm | TopBuild Corp. Quote

See the full list of top ranked stocks here

Learn more about the Growth score and how it is calculated here.    

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Legg Mason, Inc. (LM) : Free Stock Analysis Report
 
TopBuild Corp. (BLD) : Free Stock Analysis Report
 
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research